Find recruiting clinical trials for prostate cancer in the UK — from localised disease through hormone-sensitive to castration-resistant (CRPC). See your treatment pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Cancer confined to the prostate gland
Standard: Surgery (prostatectomy), radiation therapy, or active surveillance
Cancer has spread but still responds to hormone therapy
Standard: ADT + ARPI (Apalutamide, Enzalutamide, or Abiraterone)
Cancer progressing despite hormone therapy
Standard: ARPI switch, Docetaxel chemotherapy, or Radium-223 (bone mets)
After chemotherapy — clinical trials are especially important
Standard: Cabazitaxel, PARP inhibitor (if BRCA/HRR mutation), Lu-177-PSMA, or clinical trial
Prostate-Specific Antigen is the primary marker for monitoring disease progression and treatment response. Rising PSA often precedes visible progression on scans.
About 10-15% of metastatic prostate cancers have homologous recombination repair gene mutations. These patients may benefit from PARP inhibitors like olaparib or rucaparib.
Prostate-Specific Membrane Antigen is expressed on most prostate cancer cells. PSMA-targeted therapies like Lu-177-PSMA-617 represent a major advance in advanced disease.
Loading trials from ClinicalTrials.gov...